298 related articles for article (PubMed ID: 32861288)
41. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
42. Blastoid variant of mantle cell lymphoma in palatine tonsil.
Valente VB; de Castro TF; Takamiya AS; Callestini R; Xavier-Junior JCC; Cortopassi GM; Neto SC; Collado FU; Biasoli ÉR; Miyahara GI; Bernabé DG
Oral Oncol; 2021 Nov; 122():105552. PubMed ID: 34610523
[TBL] [Abstract][Full Text] [Related]
43. Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass.
De Niear MA; Greer JP; Seegmiller A; Mawn LA
Ocul Oncol Pathol; 2019 Jun; 5(4):245-251. PubMed ID: 31367585
[TBL] [Abstract][Full Text] [Related]
44. Blastoid Mantle Cell Lymphoma Presenting as an Oropharyngeal Mass.
Macapagal S; Wannaphut C; Takahashi T; Yinadsawaphan T; Nishimura Y; Acoba J
Cureus; 2024 Mar; 16(3):e56378. PubMed ID: 38633973
[TBL] [Abstract][Full Text] [Related]
45. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
[TBL] [Abstract][Full Text] [Related]
46. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
47. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
48. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression.
Vogt N; Klapper W
Histopathology; 2013 Jan; 62(2):334-42. PubMed ID: 23240716
[TBL] [Abstract][Full Text] [Related]
49. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
50. The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples.
Zhang YH; Liu J; Dawlett M; Guo M; Sun X; Gong Y
Cancer Cytopathol; 2014 Dec; 122(12):892-7. PubMed ID: 25056830
[TBL] [Abstract][Full Text] [Related]
51. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
52. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
53. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
Gauthier J; Maloney DG
Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
[TBL] [Abstract][Full Text] [Related]
54. Primary cutaneous blastoid mantle cell lymphoma-case report.
Estrozi B; Sanches JA; Varela PC; Bacchi CE
Am J Dermatopathol; 2009 Jun; 31(4):398-400. PubMed ID: 19461249
[TBL] [Abstract][Full Text] [Related]
55. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
56. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
57. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma.
Räty R; Franssila K; Jansson SE; Joensuu H; Wartiovaara-Kautto U; Elonen E
Eur J Cancer; 2003 Feb; 39(3):321-9. PubMed ID: 12565984
[TBL] [Abstract][Full Text] [Related]
58. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.
Xu J; Medeiros LJ; Saksena A; Wang M; Zhou J; Li J; Yin CC; Tang G; Wang L; Lin P; Li S
Oncotarget; 2018 Feb; 9(14):11441-11450. PubMed ID: 29545910
[TBL] [Abstract][Full Text] [Related]
59. How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR; Barrett A; Cheah CY; Eyre TA
Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
[TBL] [Abstract][Full Text] [Related]
60. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
Dreyling M; Klapper W; Rule S
Blood; 2018 Dec; 132(26):2722-2729. PubMed ID: 30385481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
